The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: A meta-analysis | Zendy

Chao Cui | Zendy; Xin Sun | Zendy; Jun Zhang | Zendy; Dong Han | Zendy; Jundong Gu | Zendy

Open Access

The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: A meta-analysis

Author(s) -

Chao Cui,

Xin Sun,

Jun Zhang,

Dong Han,

Jundong Gu

Publication year - 2014

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.145835

Subject(s) - diagnostic odds ratio , meta analysis , medicine , confidence interval , biomarker , odds ratio , likelihood ratios in diagnostic testing , lung cancer , gastroenterology , receiver operating characteristic , oncology , carcinoma , biochemistry , chemistry

The serum level of Cyfra21-1 was always elevated in patients with nonsmall cell lung carcinoma. The aim of this meta-analysis was to evaluate the serum Cyfra21-1 as a biomarker in the diagnosis of nonsmall cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research